Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 36.13
SGMO's Cash-to-Debt is ranked lower than
52% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. SGMO: 36.13 )
Ranked among companies with meaningful Cash-to-Debt only.
SGMO' s Cash-to-Debt Range Over the Past 10 Years
Min: 25.33  Med: No Debt Max: No Debt
Current: 36.13
Equity-to-Asset 0.86
SGMO's Equity-to-Asset is ranked higher than
79% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. SGMO: 0.86 )
Ranked among companies with meaningful Equity-to-Asset only.
SGMO' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.77  Med: 0.87 Max: 0.97
Current: 0.86
0.77
0.97
Interest Coverage N/A
SGMO's Interest Coverage is ranked lower than
53% of the 463 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SGMO: N/A )
Ranked among companies with meaningful Interest Coverage only.
SGMO' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: N/A
N/A
No Debt
Piotroski F-Score: 2
Altman Z-Score: 3.98
Beneish M-Score: -0.44
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -374.23
SGMO's Operating Margin % is ranked lower than
65% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -92.73 vs. SGMO: -374.23 )
Ranked among companies with meaningful Operating Margin % only.
SGMO' s Operating Margin % Range Over the Past 10 Years
Min: -374.23  Med: -119.18 Max: -58.38
Current: -374.23
-374.23
-58.38
Net Margin % -369.58
SGMO's Net Margin % is ranked lower than
66% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -81.52 vs. SGMO: -369.58 )
Ranked among companies with meaningful Net Margin % only.
SGMO' s Net Margin % Range Over the Past 10 Years
Min: -369.58  Med: -114.89 Max: -57.59
Current: -369.58
-369.58
-57.59
ROE % -44.13
SGMO's ROE % is ranked lower than
53% of the 756 Companies
in the Global Biotechnology industry.

( Industry Median: -38.58 vs. SGMO: -44.13 )
Ranked among companies with meaningful ROE % only.
SGMO' s ROE % Range Over the Past 10 Years
Min: -52.56  Med: -33.13 Max: -16.09
Current: -44.13
-52.56
-16.09
ROA % -39.03
SGMO's ROA % is ranked lower than
55% of the 855 Companies
in the Global Biotechnology industry.

( Industry Median: -33.01 vs. SGMO: -39.03 )
Ranked among companies with meaningful ROA % only.
SGMO' s ROA % Range Over the Past 10 Years
Min: -47.56  Med: -28.49 Max: -13.76
Current: -39.03
-47.56
-13.76
ROC (Joel Greenblatt) % -1764.91
SGMO's ROC (Joel Greenblatt) % is ranked lower than
68% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -496.85 vs. SGMO: -1764.91 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
SGMO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2186.87  Med: -1671.55 Max: -1066.04
Current: -1764.91
-2186.87
-1066.04
3-Year Revenue Growth Rate -13.90
SGMO's 3-Year Revenue Growth Rate is ranked lower than
68% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. SGMO: -13.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
SGMO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -37.3  Med: -2.2 Max: 67.4
Current: -13.9
-37.3
67.4
3-Year EBITDA Growth Rate 29.50
SGMO's 3-Year EBITDA Growth Rate is ranked higher than
80% of the 506 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. SGMO: 29.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
SGMO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -23.7  Med: 4.6 Max: 29.5
Current: 29.5
-23.7
29.5
3-Year EPS without NRI Growth Rate 28.60
SGMO's 3-Year EPS without NRI Growth Rate is ranked higher than
82% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. SGMO: 28.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
SGMO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -25.2  Med: -1.5 Max: 32.9
Current: 28.6
-25.2
32.9
GuruFocus has detected 4 Warning Signs with Sangamo Therapeutics Inc $SGMO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SGMO's 10-Y Financials

Financials (Next Earnings Date: 2017-05-28 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

SGMO Guru Trades in Q1 2016

Jim Simons 504,064 sh (+140.72%)
First Eagle Investment 379,727 sh (+89.86%)
Chuck Royce 456,100 sh (+46.14%)
Steven Cohen 348,200 sh (-42.00%)
» More
Q2 2016

SGMO Guru Trades in Q2 2016

Chuck Royce 456,100 sh (unchged)
Steven Cohen Sold Out
Jim Simons 114,200 sh (-77.34%)
First Eagle Investment 60,000 sh (-84.20%)
» More
Q3 2016

SGMO Guru Trades in Q3 2016

Jim Simons 594,500 sh (+420.58%)
Chuck Royce 536,100 sh (+17.54%)
First Eagle Investment Sold Out
» More
Q4 2016

SGMO Guru Trades in Q4 2016

Paul Tudor Jones 65,800 sh (New)
Chuck Royce 751,100 sh (+40.10%)
Jim Simons 321,819 sh (-45.87%)
» More
» Details

Insider Trades

Latest Guru Trades with SGMO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:VYGR, NAS:NK, OTCPK:DGJI, NAS:CALA, OTCPK:THERF, NAS:NERV, NAS:CMRX, NAS:PTI, NAS:PTCT, NAS:VCYT, AMEX:MTNB, NAS:IMGN, NAS:IDRA, OTCPK:MXDHF, OTCPK:MDGEF, OTCPK:CNBX, NAS:OCUL, OTCPK:RCAR, OTCPK:PTCHF, NAS:GERN » details
Traded in other countries:GBY.Germany, SGMO.Switzerland, 0R1D.UK,
Sangamo BioSciences Inc is a clinical stage biopharmaceutical company. The Company is engaged in the research, development & commercialization of engineered DNA-binding proteins for the development of novel therapeutic strategies for unmet medical needs.

Sangamo Therapeutics Inc was incorporated in the State of Delaware on June 22, 1995. The Company is engaged in translating ground-breaking science into genomic therapies that transform patients' lives using the company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Its proprietary zinc finger DNA-binding proteins (ZFP) technology enables efficient and highly specific genome editing and gene regulation, and are developing genome editing and gene therapies for the treatment of genetically tractable diseases.

Ratios

vs
industry
vs
history
PB Ratio 2.18
SGMO's PB Ratio is ranked higher than
70% of the 975 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. SGMO: 2.18 )
Ranked among companies with meaningful PB Ratio only.
SGMO' s PB Ratio Range Over the Past 10 Years
Min: 1.47  Med: 4.07 Max: 11.13
Current: 2.18
1.47
11.13
PS Ratio 15.27
SGMO's PS Ratio is ranked lower than
53% of the 774 Companies
in the Global Biotechnology industry.

( Industry Median: 13.23 vs. SGMO: 15.27 )
Ranked among companies with meaningful PS Ratio only.
SGMO' s PS Ratio Range Over the Past 10 Years
Min: 4.72  Med: 19.32 Max: 77.48
Current: 15.27
4.72
77.48
Current Ratio 11.25
SGMO's Current Ratio is ranked higher than
83% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. SGMO: 11.25 )
Ranked among companies with meaningful Current Ratio only.
SGMO' s Current Ratio Range Over the Past 10 Years
Min: 5.48  Med: 10.09 Max: 32.68
Current: 11.25
5.48
32.68
Quick Ratio 11.25
SGMO's Quick Ratio is ranked higher than
84% of the 820 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. SGMO: 11.25 )
Ranked among companies with meaningful Quick Ratio only.
SGMO' s Quick Ratio Range Over the Past 10 Years
Min: 5.48  Med: 10.09 Max: 32.68
Current: 11.25
5.48
32.68
Days Sales Outstanding 93.60
SGMO's Days Sales Outstanding is ranked lower than
68% of the 524 Companies
in the Global Biotechnology industry.

( Industry Median: 59.75 vs. SGMO: 93.60 )
Ranked among companies with meaningful Days Sales Outstanding only.
SGMO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.14  Med: 27.89 Max: 93.6
Current: 93.6
1.14
93.6

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.40
SGMO's 3-Year Average Share Buyback Ratio is ranked higher than
74% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. SGMO: -4.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SGMO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -61.2  Med: -9.5 Max: -1.1
Current: -4.4
-61.2
-1.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 2.46
SGMO's Price-to-Net-Cash is ranked higher than
81% of the 652 Companies
in the Global Biotechnology industry.

( Industry Median: 6.34 vs. SGMO: 2.46 )
Ranked among companies with meaningful Price-to-Net-Cash only.
SGMO' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.48  Med: 3.88 Max: 11.77
Current: 2.46
1.48
11.77
Price-to-Net-Current-Asset-Value 2.33
SGMO's Price-to-Net-Current-Asset-Value is ranked higher than
81% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. SGMO: 2.33 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
SGMO' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.43  Med: 3.79 Max: 11.02
Current: 2.33
1.43
11.02
Price-to-Tangible-Book 2.21
SGMO's Price-to-Tangible-Book is ranked higher than
75% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. SGMO: 2.21 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
SGMO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.37  Med: 3.71 Max: 7.31
Current: 2.21
1.37
7.31
Price-to-Median-PS-Value 0.79
SGMO's Price-to-Median-PS-Value is ranked higher than
69% of the 673 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. SGMO: 0.79 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SGMO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.45  Med: 1.15 Max: 6
Current: 0.79
0.45
6
Earnings Yield (Greenblatt) % -45.67
SGMO's Earnings Yield (Greenblatt) % is ranked lower than
83% of the 1109 Companies
in the Global Biotechnology industry.

( Industry Median: -10.11 vs. SGMO: -45.67 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SGMO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -163.71  Med: 0 Max: 0
Current: -45.67
-163.71
0

More Statistics

Revenue (TTM) (Mil) $19.39
EPS (TTM) $ -1.02
Beta3.64
Short Percentage of Float13.34%
52-Week Range $2.65 - 7.60
Shares Outstanding (Mil)70.88

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 17 2 2
EPS ($) -1.01 -1.35 -1.39
EPS without NRI ($) -1.01 -1.35 -1.39
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for SGMO

Headlines

Articles On GuruFocus.com
Biogen or Bluebird: Which Will Lead in SCD? Apr 30 2015 
Sangamo BioSciences Inc. Reports Operating Results (10-Q) Nov 03 2010 
Sangamo BioSciences Inc. Reports Operating Results (10-Q) Aug 05 2010 
Sangamo BioSciences Inc. Reports Operating Results (10-Q) May 05 2010 
Sangamo BioSciences Inc. Reports Operating Results (10-Q) Nov 06 2009 
Sangamo BioSciences Inc. Reports Operating Results (10-Q) Aug 03 2009 
Sangamo BioSciences Inc. Reports Operating Results (10-Q) May 05 2009 

More From Other Websites
Sangamo Therapeutics, Inc. :SGMO-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017 Mar 21 2017
SANGAMO THERAPEUTICS, INC Files SEC form 8-K, Change in Directors or Principal Officers Mar 20 2017
Sangamo Therapeutics, Inc. :SGMO-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017 Mar 14 2017
SANGAMO THERAPEUTICS, INC Financials Mar 07 2017
Sangamo Therapeutics Announces Presentation At The Cowen And Company 37th Annual Health Care... Mar 01 2017
Sangamo Therapeutics Receives Orphan Drug Designation from the FDA for SB-913 Genome Editing... Mar 01 2017
Sangamo reports 4Q loss Feb 28 2017
Sangamo reports 4Q loss Feb 28 2017
Q4 2016 Sangamo Therapeutics Inc Earnings Release - Before Market Open Feb 28 2017
SANGAMO THERAPEUTICS, INC Files SEC form 8-K, Results of Operations and Financial Condition, Change... Feb 28 2017
Sangamo Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results Feb 28 2017
Sangamo Therapeutics Announces Chief Financial Officer Succession Feb 27 2017
Sangamo Therapeutics Receives Rare Pediatric Disease Designation From FDA For SB-318 In Vivo Genome... Feb 27 2017
SANGAMO THERAPEUTICS, INC Files SEC form 8-K, Change in Directors or Principal Officers Feb 24 2017
Sangamo Therapeutics Announces Fourth Quarter And Full Year 2016 Conference Call And Webcast Feb 21 2017
Sangamo Therapeutics Announces Upcoming Presentations At The 13th Annual WORLDSymposium™ Meeting Feb 08 2017
ETFs with exposure to Sangamo Therapeutics, Inc. : January 20, 2017 Jan 20 2017
Biotech Premarket Movers: SGMO, IPXL, PTLA Jan 13 2017
Biotech Premarket Movers: IPXL, SGMO, ARLZ Jan 11 2017
Sangamo Therapeutics Receives Orphan Drug Designation from the FDA for SB-318 Genome Editing... Jan 11 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)